Market Overview:
The global α1 adrenergic agonist market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of cardiovascular diseases and rising geriatric population. Additionally, the growing demand for ophthalmic drugs is also contributing to the growth of this market. However, stringent regulatory policies and high cost associated with R&D are some of the major factors restraining the growth of this market. Based on type, phenylephrine accounted for a majority share in 2017 and is projected to maintain its dominance during the forecast period as well. This can be attributed to its wide usage in various applications such as paroxysmal supraventricular tachycardia (PSVT), eye drops, anaphylaxis and cardiac arrest among others. Methoxamine is expected to grow at a highest CAGR owing to its increasing use in emergency medical services for treating hypotension caused by sepsis or anaphylaxis shock state . By application, PSVT held a dominant share in 2017 and is projected retain its position during 2018-2030 owingtoits high incidence rate across all regions worldwide . Anaphylaxis was observed as second largest application segment due ot he increased awareness about allergic reactions coupled with rising numberof cases reported every year . Cardiac arrest was observed as third largestapplication segment due othe increased incidences offatal cardiac arrests globally .
Product Definition:
A drug that specifically binds and activates the α1 adrenergic receptor. This causes an increase in heart rate, blood pressure, and muscle contraction.
Phenylephrine:
Phenylephrine is a chemical compound that belongs to the class of drugs known as nasal decongestants. It works by widening the blood vessels in the nose and brain, reducing swelling caused due to congestion. The drug has found use in various products including topical ointments for skin allergies, oral tablets or capsules for cold symptoms, and injections for allergic reactions or cardiovascular disease complications.
Methoxamine:
Methoxamine is a dual acting α1 adrenergic agonist. It has both local anesthetic and stimulant properties. Methoxamine is used as an ingredient in some cold preparations such as nasal sprays and gels, but it's main use is in the treatment of itching associated with Scabies (Itching Pills).
Methoxamine hydrochloride tablets are approved by the Food and Drug Administration (FDA) for sale in the U.
Application Insights:
The global α1 adrenergic agonist market is segmented based on application into paroxysmal supraventricular tachycardia, cardiac arrest, eye drops, anaphylaxis and others. The paroxysmal supraventricular tachycardia segment held the largest share in 2017 owing to the high incidence of this condition which results in a shock-like state to the patient and requires immediate treatment with an oral medication. According to a study published by NCBI in 2019, around 1% of people suffer from PSVT making it one of the most common heart disorders.
The cardiac arrest segment is expected to grow at fastest rate during forecast period due largely to increasing number of reported cases worldwide due mainly to drug induced complications or adverse effects leading ultimately resulting in cardiac arrest.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period due to increasing awareness about ‘Treating Heart Failure’ and other related disorders, presence of well-established healthcare facilities, availability of advanced medical products & services, and favorable reimbursement policies. Moreover, high prevalence of PSVT in this region is one more factor responsible for dominance.
Asia Pacific is anticipated to be the fastest growing regional market during the forecast period owing to rising incidences of paroxysmal supraventricular tachycardia (PSVT), anaphylaxis due to food allergies & intolerances as well as cardiac arrests that require immediate treatment with ‘Alpha-1 adrenergic agonist’ drugs such as metoclopramide or epinephrine.
Growth Factors:
- Increasing prevalence of lifestyle diseases such as hypertension, obesity, and diabetes which leads to the increased demand for α1 adrenergic agonist drugs.
- Growing geriatric population who are more susceptible to develop hypertension and other cardiovascular diseases, thereby driving the demand for α1 adrenergic agonist drugs.
- Rising awareness about the benefits of using α1 adrenergic agonist drugs for treating various medical conditions is expected to boost market growth during the forecast period.
- Technological advancements in drug delivery systems that would make these drugs more accessible and affordable is likely to propel market growth in coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
α1 Adrenergic Agonist Market Research Report
By Type
Phenylephrine, Methoxamine, Midodrine, Oxymetazoline
By Application
Paroxysmal Supraventricular Tachycardia, Eye Drops, Anaphylaxis, Cardiac Arrest, Anaphylaxis, Cardiac Arrest, Others
By Companies
Bausch Health Companies, Pfizer, Sterling Winthrop, Sanofi, Paragon BioTeck, West-Ward Pharmaceuticals , Biosyent Pharma , Novartis, Omega Laboratories, Medical Purchasing Solutions, Avadel Legacy Pharmaceuticals, Amneal Biosciences, Cipla USA, Par Pharmaceutical, Glaxosmithkline, Teva, Bayer, Impax Generics, Mylan Pharmaceuticals, Physicians Total Care, Merck
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global α1 Adrenergic Agonist Market Report Segments:
The global α1 Adrenergic Agonist market is segmented on the basis of:
Types
Phenylephrine, Methoxamine, Midodrine, Oxymetazoline
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Paroxysmal Supraventricular Tachycardia, Eye Drops, Anaphylaxis, Cardiac Arrest, Anaphylaxis, Cardiac Arrest, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bausch Health Companies
- Pfizer
- Sterling Winthrop
- Sanofi
- Paragon BioTeck
- West-Ward Pharmaceuticals
- Biosyent Pharma
- Novartis
- Omega Laboratories
- Medical Purchasing Solutions
- Avadel Legacy Pharmaceuticals
- Amneal Biosciences
- Cipla USA
- Par Pharmaceutical
- Glaxosmithkline
- Teva
- Bayer
- Impax Generics
- Mylan Pharmaceuticals
- Physicians Total Care
- Merck
Highlights of The α1 Adrenergic Agonist Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Phenylephrine
- Methoxamine
- Midodrine
- Oxymetazoline
- By Application:
- Paroxysmal Supraventricular Tachycardia
- Eye Drops
- Anaphylaxis
- Cardiac Arrest
- Anaphylaxis
- Cardiac Arrest
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the α1 Adrenergic Agonist Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
u00ceu00b11 adrenergic agonist is a medication that stimulates the release of adrenaline. It is used to treat a variety of conditions, including anxiety, panic attacks, and heart problems.
Some of the major companies in the î±1 adrenergic agonist market are Bausch Health Companies, Pfizer, Sterling Winthrop, Sanofi, Paragon BioTeck, West-Ward Pharmaceuticals , Biosyent Pharma , Novartis, Omega Laboratories, Medical Purchasing Solutions, Avadel Legacy Pharmaceuticals, Amneal Biosciences, Cipla USA, Par Pharmaceutical, Glaxosmithkline, Teva, Bayer, Impax Generics, Mylan Pharmaceuticals, Physicians Total Care, Merck.
The ±1 adrenergic agonist market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 α1 Adrenergic Agonist Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 α1 Adrenergic Agonist Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 α1 Adrenergic Agonist Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the α1 Adrenergic Agonist Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global α1 Adrenergic Agonist Market Size & Forecast, 2018-2028
4.5.1 α1 Adrenergic Agonist Market Size and Y-o-Y Growth
4.5.2 α1 Adrenergic Agonist Market Absolute $ Opportunity
Chapter 5 Global α1 Adrenergic Agonist Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 α1 Adrenergic Agonist Market Size Forecast by Type
5.2.1 Phenylephrine
5.2.2 Methoxamine
5.2.3 Midodrine
5.2.4 Oxymetazoline
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global α1 Adrenergic Agonist Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 α1 Adrenergic Agonist Market Size Forecast by Applications
6.2.1 Paroxysmal Supraventricular Tachycardia
6.2.2 Eye Drops
6.2.3 Anaphylaxis
6.2.4 Cardiac Arrest
6.2.5 Anaphylaxis
6.2.6 Cardiac Arrest
6.2.7 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global α1 Adrenergic Agonist Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 α1 Adrenergic Agonist Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America α1 Adrenergic Agonist Analysis and Forecast
9.1 Introduction
9.2 North America α1 Adrenergic Agonist Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America α1 Adrenergic Agonist Market Size Forecast by Type
9.6.1 Phenylephrine
9.6.2 Methoxamine
9.6.3 Midodrine
9.6.4 Oxymetazoline
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America α1 Adrenergic Agonist Market Size Forecast by Applications
9.10.1 Paroxysmal Supraventricular Tachycardia
9.10.2 Eye Drops
9.10.3 Anaphylaxis
9.10.4 Cardiac Arrest
9.10.5 Anaphylaxis
9.10.6 Cardiac Arrest
9.10.7 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe α1 Adrenergic Agonist Analysis and Forecast
10.1 Introduction
10.2 Europe α1 Adrenergic Agonist Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe α1 Adrenergic Agonist Market Size Forecast by Type
10.6.1 Phenylephrine
10.6.2 Methoxamine
10.6.3 Midodrine
10.6.4 Oxymetazoline
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe α1 Adrenergic Agonist Market Size Forecast by Applications
10.10.1 Paroxysmal Supraventricular Tachycardia
10.10.2 Eye Drops
10.10.3 Anaphylaxis
10.10.4 Cardiac Arrest
10.10.5 Anaphylaxis
10.10.6 Cardiac Arrest
10.10.7 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific α1 Adrenergic Agonist Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific α1 Adrenergic Agonist Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific α1 Adrenergic Agonist Market Size Forecast by Type
11.6.1 Phenylephrine
11.6.2 Methoxamine
11.6.3 Midodrine
11.6.4 Oxymetazoline
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific α1 Adrenergic Agonist Market Size Forecast by Applications
11.10.1 Paroxysmal Supraventricular Tachycardia
11.10.2 Eye Drops
11.10.3 Anaphylaxis
11.10.4 Cardiac Arrest
11.10.5 Anaphylaxis
11.10.6 Cardiac Arrest
11.10.7 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America α1 Adrenergic Agonist Analysis and Forecast
12.1 Introduction
12.2 Latin America α1 Adrenergic Agonist Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America α1 Adrenergic Agonist Market Size Forecast by Type
12.6.1 Phenylephrine
12.6.2 Methoxamine
12.6.3 Midodrine
12.6.4 Oxymetazoline
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America α1 Adrenergic Agonist Market Size Forecast by Applications
12.10.1 Paroxysmal Supraventricular Tachycardia
12.10.2 Eye Drops
12.10.3 Anaphylaxis
12.10.4 Cardiac Arrest
12.10.5 Anaphylaxis
12.10.6 Cardiac Arrest
12.10.7 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) α1 Adrenergic Agonist Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) α1 Adrenergic Agonist Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) α1 Adrenergic Agonist Market Size Forecast by Type
13.6.1 Phenylephrine
13.6.2 Methoxamine
13.6.3 Midodrine
13.6.4 Oxymetazoline
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) α1 Adrenergic Agonist Market Size Forecast by Applications
13.10.1 Paroxysmal Supraventricular Tachycardia
13.10.2 Eye Drops
13.10.3 Anaphylaxis
13.10.4 Cardiac Arrest
13.10.5 Anaphylaxis
13.10.6 Cardiac Arrest
13.10.7 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 α1 Adrenergic Agonist Market: Competitive Dashboard
14.2 Global α1 Adrenergic Agonist Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bausch Health Companies
14.3.2 Pfizer
14.3.3 Sterling Winthrop
14.3.4 Sanofi
14.3.5 Paragon BioTeck
14.3.6 West-Ward Pharmaceuticals
14.3.7 Biosyent Pharma
14.3.8 Novartis
14.3.9 Omega Laboratories
14.3.10 Medical Purchasing Solutions
14.3.11 Avadel Legacy Pharmaceuticals
14.3.12 Amneal Biosciences
14.3.13 Cipla USA
14.3.14 Par Pharmaceutical
14.3.15 Glaxosmithkline
14.3.16 Teva
14.3.17 Bayer
14.3.18 Impax Generics
14.3.19 Mylan Pharmaceuticals
14.3.20 Physicians Total Care
14.3.21 Merck
